Dendritic cells in pancreatic cancer immunotherapy: Vaccines and combination immunotherapies

PMID: 31676092
Journal: Pathology, research and practice (volume: 215, issue: 12, Pathol. Res. Pract. 2019 Dec;215(12):152691)
Published: 2019-10-17

Yang J, Shangguan J, Eresen A, Li Y, Wang J, Zhang Z


Despite significant advances over the past decades of research, pancreatic cancer (PC) continues to have the worst 5-year survival of any malignancy. Dendritic cells (DCs) are the most potent professional antigen-presenting cells and are involved in the induction and regulation of antitumor immune responses. DC-based immunotherapy has been used in clinical trials for PC. Although safety, efficacy, and immune activation were reported in patients with PC, DC vaccines have not yet fulfilled their promise. Additional strategies for combinatorial approaches aimed to augment and sustain the antitumor specific immune response elicited by DC vaccines are currently being investigated. Here, we will discuss DC vaccination immunotherapies that are currently under preclinical and clinical investigation and potential combination approaches for treating and improving the survival of PC patients.